In the LEADER trial [35], treatment with GLP-1 analogues had a positive effect on a composite cardiovascular outcome consisting of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. This evidence concerns the gene GCG and myocardial infarction.